Patents by Inventor Karl F. Swingle

Karl F. Swingle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Publication number: 20040242620
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokin induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Application
    Filed: December 17, 2003
    Publication date: December 2, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Patent number: 6696076
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 24, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2 MEDIATED AND RELATED DISEASES
    Publication number: 20030206868
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Application
    Filed: May 20, 2003
    Publication date: November 6, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Patent number: 6610319
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: August 26, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Publication number: 20020041887
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/1L-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Application
    Filed: December 19, 2000
    Publication date: April 11, 2002
    Applicant: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Immine response modifier compounds for treatment of TH2 mediated and related diseases
    Patent number: 6200592
    Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: March 13, 2001
    Assignee: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Patent number: 6039969
    Abstract: Immune response modifier compounds--imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines--are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: March 21, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle